### Optimization of Health and Health Delivery: A Technology Overview

#### Sanjay Mehrotra Industrial Engineering and Management Sciences <u>mehrotra@iems.northwestern.edu</u> 847 491 3155

Co-Authors on various papers: Ashley Davis, Kibaek Kim, Mark Daskin, Jane Holl, Daniela Ladner, John Friedewald, Anton Skaro, Michael Abecassis, Reuben Thomas, Olga Lyandres, Richard P. Van Duyne, Joseph T. Walsh, Matthew R. Glucksberg, Carlos J. Paredes, Eleftherios T. Papoutsakis, and Vassily Hatzimanikatis

Methodology work funded by: National Science Foundation under grants NSF CMMI-1100868, NSF-CMMI-0928936, NSF-CMMI-0727532, Office of Naval Research grants ONR-N00014-09-10518, Department of Energy grant DOE-SP0011568, NIH R01 GM065475, NIH-1R36HS021078-01

Images used in the presentation are taken from http://www.google.com/imghp

### Outline

- Understanding Optimization
- Univariate Decisions (non-dichotomous) with Data Uncertainty
  - Example: Nurse Shift Planning
- Robust Predictive Modeling Multivariate Decisions; Few Data Samples
  - Example: Glucose/Pyridine Concentration Predictive Modeling
- Designing Networks
  - Example: Addressing Geographic Inequity in Kidney Allocation
- Reverse Engineering an Underlying Mechanism Longitudinal Data
  - Example: Gene Regulatory Networks
- Multi-Objective Decision Making
  - Example: National Diabetes Budget Allocation for Prevention Programs

### **Optimization Problem Structure**

### **Objective**



#### **Constraint**



Available Resource Structural Requirements Ambiguity in Data

### **Decisions**



How Much? -- Quantity When? – Timing/Policy Which? – Selection Where? -- Locations How? – Mechanism Design Who? -- Scheduling

### **How Many Valentine Gift Boxes to Order?**



### **Elements of the Management Decision Problem**



- Demand uncertainty
- An integer decision
- A reward function
- Decision before demand is realized
- Need a systematic method for finding the "best decision"

### **Demand Distribution**



### **Profit as a Function of Demand**

Profit = Sales Revenue + Salvage Value – Purchase Price

- Scenario 1:
   Assume Order Quantity q = 700, Demand d=500
   *Profit* =18 \* 500 + 5 \* (700-500) 7 \* 700
   = \$5,100
- Scenario 2:

$$q = 700, d=1000$$
  
 $Profit = 18 * 700 + 5 * (0) - 7 * 700$   
 $= $7,700$ 

For a given order quantity (q) depending on the demand we have different values profits!

### **Writing Profits Using Symbols**

Profit = Sales Revenue + Salvage Value – Purchase Price We can only sell minimum of demand and order quantity  $\int Q = p \min(d,q) + s \max(0,q-d) - c q$ Sales Revenue Salvage Revenue Purchasing Cost

### **Expected Profit for a Given Order Quantity**

	Order Quantity $q = 700$						
Demand	Probability	Profit	Probability				
di	<b>p</b> i		* Profit				
400	.005	3800	19				
500	.01	5100	51				
600	.02	6400	128				
700	.04	7700	308				
800	.07	7700	539				
900	.11	7700	847				
1,000	.15	7700	1155				
1,100	.19	7700	1463				
1,200	.15	7700	1155				
1,300	.11	7700	847				
1,400	.07	7700	539				
1,500	.04	7700	308				
1,600	.02	7700	154				
1,700	.01	7700	77				
1,800	.005	7700	38.5				
E	xpected Value of	Profit	7628.5				

- For each order quantity profit is a random variable.
- We calculate expected value of profit function, which is random for a given order quantity.
- We want know the "best" order quantity, i.e. one that maximizes expected profit!

### **Finding the Optimal Quantity**

Order	Expected
Quantity	Profit
400	\$ 4,400
500	\$ 5,494
600	\$ 6,574
700	\$ 7,628
800	\$ 8,631
900	\$ 9,542
1,000	\$ 10,311
1,100	\$ 10,884
1,200	\$ 11,211
1,300	\$ 11,342
1,400	\$ 11,331
1,500	\$ 11,228
1,600	\$ 11,074
1,700	\$ 10,894
1,800	\$ 10,700

**Expected Value of Profit as a Function of Order Quantity** 



 At optimum: Expected cost of lost sales due to under stocking = Expected cost of overstocking

### **Shift Staffing Levels**

Situation: Need to staff a shift cost-effectively while not compromising patient safety

**Common Practice**: Staff with a mix of permanent and temporary (agency or float) nurses

**Question**: How many permanent nurses to use?

An Approach:

"Cost" := the per shift salary of a permanent RN "Stock-Out Price" := daily per shift salary of a temporary RN "Salvage Value" := benefit of having an extra permanent RN

Total Cost = Regular staffing cost + under staffing costs + overstaffing costs



"Distribution-Robust Newsvendor Models for Shift Nurse Demand Estimation", Ashley Davis, Sanjay Mehrotra, Mark Daskin and Jane Holl (under review Asia Pacific Journal of Operations Research)

### Predictive Modeling with Limited Noisy Experimental Data



"Prediction range estimation from noisy Raman spectra with robust optimization", Olga Lyandres, Richard P. Van Duyne, Joseph T. Walsh, Matthew R. Glucksberg and Sanjay Mehrotra, *Analyst*, 135, 2111-2118, 2010

### **Predictive Modeling with Experimental Data**

**Question**: How to predict true concentrations using limited calibration data?

**Problem**: Calibration data is noisy and system is over determined.

**Current Practice**: Using Partial Least-squares from Statistics which is meant to filter noise and give prediction.

# Alternative Approach: Build Robust Least-squares based optimization model

"Prediction range estimation from noisy Raman spectra with robust optimization", Olga Lyandres, Richard P. Van Duyne, Joseph T. Walsh, Matthew R. Glucksberg and Sanjay Mehrotra, *Analyst*, 135, 2111-2118, 2010

### **Predictive Modeling with Experimental Data**



#### Calibration

[c]<sub>a</sub>=10, 20, 40, 60, 100, 150, 250, 350, 450 mg/dL

#### Validation

[c]<sub>a</sub>=15, 50, 80,120, 200, 300 mg/dL

10 spectra at each concentration, baseline corrected, normalized

"Prediction range estimation from noisy Raman spectra with robust optimization", Olga Lyandres, Richard P. Van Duyne, Joseph T. Walsh, Matthew R. Glucksberg and Sanjay Mehrotra, *Analyst*, 135, 2111-2118, 2010

### **Robust Least-square Framework**



### **Results: A pyridine System**



# True value is out of prediction interval in 12/15 times.

True value is out of prediction interval in 4/15 times.

"Prediction range estimation from noisy Raman spectra with robust optimization", Olga Lyandres, Richard P. Van Duyne, Joseph T. Walsh, Matthew R. Glucksberg and Sanjay Mehrotra, *Analyst*, 135, 2111-2118, 2010

### **Results: Comparison with all Popular PLS Methods**

	<b>Robust optimization</b>	imization Partial least squares (PLS) prediction – 99% prediction interval							
concentration	(RO) prediction range	Bootstrap method	Faber 96 method	Serneels method	Phatak method				
		Pyridine conce	entrations (% v/v)	12.20 4.46/ 9.02*	11 (2 (21/ 9.02*				
5	5.14 - 8.00/3.97	-11.810.05/-0.92*	-11.050.21/-8.92*	-13.384.40/-8.92*	-11.050.21/-8.92*				
10	8.6 - 17.37/8.87	-0.52 - 4.48/1.98*	-0.49 - 4.45/1.98*	-0.62 - 4.58/1.98*	-0.49 - 4.45/1.98*				
15	14.3 - 19.85/17.66#	10.41 - 15.32/12.87	10.42 - 15.31/12.87	10.41 - 15.32/12.87	10.42 - 15.31/12.87				
25	24.96 - 26.7/25.87	25.08 - 29.90/27.49*	25.09 - 29.90/27.49*	24.97 - 30.01/27.49	25.09 - 29.90/27.49*				
30	30.19 - 32.57/31.47*	33.18 - 38.08/35.63*	33.21 - 38.05/35.63*	32.89 - 38.36/35.63*	33.21 - 38.05/35.63*				
35	35.75 - 36.88/36.16*	35.27 - 40.09/37.68*	35.27 - 40.08/37.68*	35.24 - 40.11/37.68*	35.27 - 40.08/37.68*				
45	44.32 - 48.64/44.98	40.15 - 45.30/42.72	40.27 - 45.18/42.72	39.55 - 45.90/42.72	40.27 - 45.18/42.72				
50	47.47 - 54.64/50.24	44.41 - 49.60/47.01*	44.41 - 49.60/47.01*	43.07 - 50.94/47.01	44.41 - 49.60/47.01*				
55	52.62 - 59.35/54.85	49.91 - 54.97/52.44*	50.01 - 54.87/52.44*	49.60 - 55.28/52.44	50.01 - 54.87/52.44*				
65	61.65 - 67.98/65.47	59.48 - 64.55/62.02*	59.58 - 64.45/62.02*	59.07 - 64.96/62.02*	59.58 - 64.45/62.02*				
70	68.08 - 75.62/71.93	65.43 - 70.80/68.11	65.62 - 70.60/68.11	65.40 - 70.83/68.11	65.62 - 70.60/68.11				
75	71.96 - 77.61/75.43	69.64 - 74.66/72.15*	69.75 - 74.54/72.15*	69.59 - 74.70/72.15*	69.75 - 74.54/72.15*				
85	80.52 - 85.66/83.25	79.58 - 84.90/82.24*	79.82 - 84.66/82.24*	79.44 - 85.03/82.24	79.82 - 84.66/82.24*				
90	86.50 - 89.31/87.2*	83.79 - 88.85/86.32*	83.89 - 88.74/86.32*	83.43 - 89.21/86.32*	83.89 - 88.74/86.32*				
95	90.08-93.41/91.16*	88.08 - 93.06/90.57*	88.13 - 93.00/90.57*	87.82 - 93.31/90.57*	88.13 - 93.00/90.57*				
Mean Range	4.38	5.1	4.93	5.84	4.93				
<b>Relative error</b>	0.81	2.04	2.12	2.95	2.12				
RMSEP	1.7	5.1	5.1	5.1	5.1				

\* indicates when actual value is not included in prediction range or interval

# coefficients initialized to values determined by least squares solution, for all other samples coefficients were initialized to 0.1

### **Other Examples**



Classification

Recognition

Clustering

### **Geographic Disparity in Kidney Allocation**



#### 2000-2009 Median Waiting Time Variability



#### If you live in...

IL: 2.7 years vs WI: 1.4 years NY: 3.0 years vs PA: 1.6 years

In Collaboration with:

Ashley E Davis, Mark S Daskin, Daniela P Ladner, John J Friedewald, Anton I Skaro, and Michael M Abecassis,

### **Geographic Disparity in Kidney Allocation**



Ratio: Transplanted patients relative to waitlisted patients that year

### **United Network for Organ Sharing (UNOS)**

- Created by the National Organ Transplant Act in 1984
  - Facilitate all Organ Donation and Transplantation in the US





**M**<sup>c</sup>Cormick

Northwestern Engineering

### Current Geographic Kidney Allocation: Local – Regional – National

"National"



Northwestern University Transplant Outcomes Research Collaborative Patient Safety • Quality of Life • Informed Consent & Disparities Access & Allocation • Risk Prediction & Economics • Health Informatics M<sup>c</sup>Cormick

Northwestern Engineering

### **Actual 2009 DSA "Good Kidney" Sharing**



### **Proposed KSHARE Sharing Strategy**



### **KSHARE Optimization Model**

### Assumptions

- All patients treated the 1. same
- 2. All kidneys accepted as optimal results dictate

### **Objectives**

- Minimize DSA Transplant Rate Variability

  - $rate_{DSA} = \frac{Kidney \, Transplants \, in \, DSA}{Waitlist \, population \, in \, DSA}$
  - Equitable by the Institute of Medicine
- Maintain current local allocation
- 10 year phase-in with minimal: ٠
  - **DSA Sharing Partnerships**
  - Changes to Yearly Sharing Strategy

Northwestern University Transplant Outcomes Research Collaborative Patient Safety • Quality of Life • Informed Consent & Disparities Access & Allocation • Risk Prediction & Economics • Health Informatic

### **KSHARE** Inputs

#### Sets

- I: Set of all DSAs in the Continental US
- DSA(i): Set of Feasible Sharing DSAs for DSA i, including i

#### Parameters

- *w(i)*: DSA *i* Waitlist on Jan 1, 2000
- g(i,t): DSA *i* Waitlist Registrations Non-Transplant Removals in Year 200*t*
- maxTR, minTR: Limits on transplant rate range to be attained by 2009
- *I(i)*: Yearly percentage of locally allocated kidneys in DSA *i*
- *s(i,t)*: DSA *i* kidney procurement in year 200*t*
- M >>0, T = 10 years,  $\varphi = 10^{-8}$  (scaling parameter)
- Variables
  - A(i,j,t): Kidneys allocated from DSA i to DSA j in year 200t
  - WL(i,t): DSA i Waitlist size on January 1<sup>st</sup>, 200t
  - TX(i,t): DSA i total kidney transplants in year 200t
  - SP(i,j): equals 1 if DSA *i* ever shares kidneys with DSA *j*
  - FS(*i*,*j*,*t*): Percent of DSA *i* procurement allocated to DSA *j* in year 200*t*
  - maxFS(i,j), minFS(i,j): Max/Min annually percent of DSA i kidneys allocated to DSA j

Northwestern University Transplant Outcomes Research Collaborative Patient Safety • Quality of Life • Informed Consent & Disparities Access & Allocation • Risk Prediction & Economics • Health Informatics

### **KSHARE Formulation**

Northwestern University	
Transplant Outcomes	<b>Research Collaborative</b>
Patient Safety • Quality of Life •	Informed Consent & Disparities
Access & Allocation	on & Economics • Health Informatics

### **KSHARE Formulation**

(sharePair(i, j) + maxSharedLim(i, j) - minSharedLim(i, j))minimize: All DSA j in FeasibleDSAs(i) waitlistSize(i, 0) = initialWaitlist(i)waitlistSize (i, t + 1) = waitlistSize(i, t) + growthInWaitlist(i, t) - transplants(i, t)transplants(i, t) =allocation(j, i, t) All DSAs j in FeasibleDSAs(i)  $localAllocation(i) * kidneysProcured(i, t) \le sharedAllocation(i, i, t)$ allocation(i, j, t) = kidneysProcured(i, t) All DSAs j in FeasibleDSAs(i) minRateLim \* waitlistSize(i, T)  $\leq$  transplants(i, T)  $\leq$  maxRateLim \* waitlistSize(i, T)  $allocation(i, j, t) \leq M * sharePair(i, j)$ All Years t fracShared(i, j, t) \* kidneysProcured(i, t) = allocation(i, j, t) minSharedLim(i, j)  $\leq$  fracShared(i, j, t)  $\leq$  maxSharedLim(i, j)

Northwestern Engineering

### **Effect of Sharing Radius**

DSA Transplant	Actual		Feasible Sharing Radius, miles						
Rate Statistic	2009	370	450	500	600	900	1,200	1,500	2,700
Min Rate (%)	3.0	4.3	4.5	4.6	5.0	5.8	6.3	6.5	6.6
Max Rate (%)	30.0	30.0	15.0	12.5	12.5	12.5	12.5	12.4	12.4
Max Rate/Min Rate	10	7.0	3.3	2.7	2.5	2.2	2.0	1.9	1.9
Range in Rates (%)	27.0	25.7	10.5	7.9	7.5	6.7	6.2	5.9	5.9
									F

Only small reductions in: Range in Rates: 1.6% Max/Min Ratio: 0.6

#### **Lessons Learned**

• Global sharing is not required to fix the inequity problem



### **Comparison of 2000-2009 Allocation**

	Actual Allocation					600 mile Allocation				
Year	Min Rate (%)	Max Rate (%)	Range (%)	Max Rate <sub>/</sub> Min Rate	Min Rate (%)	Max Rate (%)	Range (%)	Max Rate <sub>/</sub> Min Rate		
2000	5.1	54.5	49.4	10.6	6.9	54.5	47.6	7.9		
2001	5.1	54.6	49.5	10.8	5.9	38.3	32.4	6.5		
2002	5.5	45.0	39.5	8.2	5.5	38.3	32.8	6.9		
2003	4.7	44.1	39.4	9.4	4.7	39.5	34.8	8.4		
2004	4.0	60.3	56.3	15	5.0	31.8	26.8	6.4		
2005	3.9	45.8	42.0	11.9	4.4	25.0	20.6	5.7		
2006	4.3	49.6	45.3	11.5	5.3	25.9	20.7	4.9		
2007	4.4	37.7	33.3	8.6	4.4	23.4	19.0	5.3		
2008	4.0	29.5	25.5	7.3	4.8	23.0	18.2	4.8		
2009	3.0	29.9	27.0	10	5.0	12.5	7.5	2.5		

Northwestern University Transplant Outcomes Research Collaborative Patient Safety • Quality of Life • Informed Consent & Disparities Access & Allocation • Risk Prediction & Economics • Health Informatics **M**<sup>c</sup>Cormick

Northwestern Engineering

### **Yearly KSHARE Sharing**



Northwestern University Transplant Outcomes Research Collaborative Patient Safety • Quality of Life • Informed Consent & Disparities Access & Allocation • Risk Prediction & Economics • Health Informatics **M<sup>c</sup>Cormick** 

Northwestern Engineering

### **Other Examples**



#### Routing of Home Health Services [1]



#### **Design of Communities and/or Rural Infrastructure** [2]

[1] An Integrated Spatial DSS for Scheduling and Routing Home-Health-Care Nurses, SV. Begur, D.M. Miller, and JR Weaver, Interfaces, 1997, 27(4). [2] "Improving accessibility to rural health services: The maximal covering network improvement problem," by Lisa Murawski, Richard L. Church, Socio-Economic Planning Sciences, 43(2), 2009

### **Reverse Engineering of Gene Regulatory Networks**



**Time-course variation of subset of important genes in the sporulation cascade of** *B. Anthracis*. The time-course (in hours) variation of the logarithm of expression ratios in color-coded format (green indicates up-regulation, red indicates down-regulation, grey indicates missing data and the intensity of the color indicates the level of regulation) of 24 important genes in the sporulation cascade of *B. anthracis*.

"A Model-based optimization framework for the inference of regulatory interactions using time-course DNA microarray expression data", Reuben Thomas, Carlos J. Paredes, Sanjay Mehrotra, Eleftherios T. Papoutsakis, and Vassily Hatzimanikatis, BMC Bioinformatics, 8:228, 2007.

### **Expressions from different Regulatory Networks**



**Time profiles of log mRNA expression ratios for three representative synthetic networks**. Logarithm of mRNA expression ratios as a function of time for three networks. The network in (a), "Low" results in a relatively lower degree of similarity between the different gene-expression patterns in the system, the network in (b), "Medium" in a medium degree of similarity, while the network in (c), "High" results in a relatively high degree of similarity. The units of time are arbitrary but are consistent with the units of the parameters of the system.

### **Mathematical Formulation for the Network Design**

$$\min \sum_{j=1}^{N_t} \left( \log \left( \frac{d\tilde{m}_i(t_j)}{dt} + \beta_i \tilde{m}_i(t_j) \right) - \log(\alpha_i) - \sum_{g=1}^n \varepsilon_{ig} \log(\tilde{p}_g(t_j)) \right)^2 + \tau_i^2 ||\overline{\varepsilon_i}||^2$$
(9)

subject to

$$DY_{ij} \le \varepsilon_{ij} \le DY_{ij}, j = 1, 2, \dots, n$$
(10)

$$\sum_{j=1}^{N} Y_{ij} \le k \tag{11}$$

$$Y_{ij} \in \{0,1\}, i, j = 1, 2, \dots, n$$
 (12)

$$\log(\alpha_i) \ge -A \tag{13}$$

### **Mathematical Formulation for the Network Design**



Variation of correct identifications and identification errors with experimental samples and discretizations for "Low" network. Variation of the percentage of correctly identified interactions among 30 known interactions and the error as a percentage of the error obtained with the smallest number of samples. The variations are with respect to the number of experimental samples chosen and the number of discretizations, *Nt*. The "experimental" data are obtained by simulation using the "Low" synthetic network (see Figure 1).

### **Multi-Expert Multi-Objective Decision Making**

Situation: Centers for Disease Control and Prevention allocates diabetes budgets to different states for improving diabetic outcomes every year.

**Question**: How to allocate limited budget to the different states? Which Risk/Outcome criterion to use?

**Problem**: Stakeholders have different opinions about how to allocate money to states!

**Current Practice**: Don't know, but budgets are not correlated with patient outcomes

"Outcome Based State Budget Allocation for Diabetes Prevision Programs Using Multi-Criteria Optimization with Robust Weights," Sanjay Mehrotra, and Kibaek Kim, *Health Care Management Sciences*, 2011

### **Diabetes Prevalence & Comorbidities Vary**

#### Percentage of Diabetic Population

#### End Stage Renal Disease







### Decision Criteria from: Behavioral Risk Factor Surveillance Survey (BRFSS) Data

Decision	
Criteria	Description
1-1.	the average number of times for checking feet sores and irritations by a health professional in the
	past 12 month
1-2.	the average number of times for checking feet sores and irritations by themselves in the past 12
	month
1-3.	the number of diabetic patients who have ever had feet sores or irritations for more than four weeks
2-1.	the number of diabetic patients who have not had an eye exam more than a month
2-2.	the number of diabetic patients having eyes affected by diabetes or having retinopathy
3-1.	the number of diabetic patients who have not had a flu shot during the past 12 months
3-2.	the number of diabetic patients who have not had a pneumonia shot during the past 12 months
4-1.	the average number of times for having a health professional checked for Hemoglobin A1c level
4-2.	the average number of times for personal checking blood glucose level
5-1.	the gap between the maximum and the minimum of the prevalence among races/ethnicities
6-1.	the number of diabetic patients who have ever diagnosed with heart attack
6-2.	the number of diabetic patients who have ever diagnosed with angina or coronary heart disease
6-3.	the number of diabetic patients who have ever diagnosed with stroke
6-4.	the number of diabetic patients who have not checked blood cholesterol more than one year
6-5.	the number of diabetic patients who have ever diagnosed with high blood cholesterol
6-6.	the number of diabetic patients who have ever diagnosed with high blood pressure
6-7.	the number of diabetic patients who are currently smoking
6-8.	the number of obese diabetic patients
6-9.	the number of diabetic patients who did not participate any physical activities or exercise during
	the past month
7-1.	the average number of times for seeing health professionals for diabetes in the past 12 months
7-2.	the number of diabetic patients who have never taken classes in managing diabetes
7-3.	the number of people who have been diagnosed as diabetes
8-1.	the crude rate of adults initiating treatment for diabetes-related ESRD
9-1.	the number of deaths per 1,000 population

### **Mapping Criteria to National Diabetes Objectives**

	Decision Criteria Group			
#	(#  of criteria)	Data Source	NDO [21]	ICD-9
1	Limb Amputation $(3)$	BRFSS	1	250.6
2	Blindness $(2)$	BRFSS	2	250.5
3	Influenza and Pneumonia $(2)$	BRFSS	3	-
4	Glucose Control $(2)$	BRFSS	4	250.1 - 250.3
5	Disparity $(1)$	BRFSS	5	-
6	Cardiac $(9)$	BRFSS	6	250.7
7	Diabetic Prevalence $(3)$	BRFSS	-	250.8 - 250.9
8	Renal Failure $(1)$	NDSS	-	250.4
9	Mortality	WONDER $(1)$	-	-

### Retrospective Principal Component Analysis (PCA) of the CDC Budget

		Princ	ipal Co	mponents	
	Criteria	1	2	3	$\operatorname{Communality}$
)9	Budget	0.30	-0.28	-0.66	0.60
	1-1	-0.25	0.95	0.10	0.97
	1-2	-0.23	0.95	0.06	0.95
	1-3	0.95	0.01	-0.11	0.92
	2-1	0.96	-0.27	-0.07	1.00
	2-2	0.95	0.01	-0.10	0.91
	3-1	0.96	-0.25	-0.06	0.98
	3-2	0.97	-0.20	-0.06	0.99
	4-1	-0.21	0.95	-0.04	0.95
	4-2	-0.26	0.95	0.12	0.98
	5 - 1	0.75	-0.41	0.01	0.73
	6-1	0.91	-0.34	-0.08	0.96
	6-2	0.95	-0.28	-0.09	0.99
	6-3	0.93	-0.31	-0.06	0.97
	6-4	0.95	-0.24	0.02	0.96
	6-5	0.95	-0.28	-0.09	0.99
	6-6	0.95	-0.29	-0.07	1.00
	6-7	0.87	-0.41	-0.03	0.93
	6-8	0.93	-0.34	-0.07	0.99
	6-9	0.91	-0.36	-0.05	0.96
	7-1	-0.22	0.95	0.05	0.96
	7-2	0.96	0.01	-0.10	0.92
	7-3	0.96	-0.28	-0.07	1.00
	8-1	0.01	-0.04	0.88	0.77
	9-1	0.92	-0.30	-0.12	0.95

*Principal component values*: the bivariate correlations between the actual data and the corresponding component.

*The communality values:* represent how well all the principal components can explain the variation in the observed data

All data is explained by 2 components, except Budget and ESRD which needs 3<sup>rd</sup>.

ESRD and Budget have "negative correlation"

Budget can not be explained by the risk criteria!

### Diabetic Relative Risk Measure and Excess Risk Function

					r	
	Limp Amputation					Excess Risk
State	Risk	<b>Glycemic Risk</b>	<b>Health Disparity</b>	Mortality	Budget	of Mortality
Alabama	0.007135	0.005188	0.033331	0.031085	0.012626	0.018459
Alaska	0.093590	0.103378	0.003743	0.002332	0.017833	0.000000
Arizona	0.007471	0.006835	0.021334	0.025801	0.016535	0.009265
Arkansas	0.013907	0.011237	0.014212	0.017949	0.012481	0.005469
California	0.001529	0.001240	0.111161	0.157799	0.136228	0.021571
Colorado	0.014551	0.013602	0.020933	0.014483	0.013602	0.000882
Connecticut	0.015555	0.009757	0.023900	0.016730	0.010192	0.006538
Delaware	0.045371	0.051390	0.005189	0.004086	0.025840	0.000000
District of Columbia	0.078343	0.043969	0.005211	0.003936	0.043969	0.000000
Florida	0.002460	0.001507	0.079745	0.110648	0.093641	0.017006

Relative risk across states for each risk factor

#### **Excess Risk/Utility Function:**

$$f_j(\mathbf{x}) = \sum_{i=1}^n \max(z_{ij} - x_i, 0), \ j = 1, ..., m$$

Relative risk of criterion *i* in state *j* 

Allocated budget in state *j* 

### Possible Weights for Classical Weighted Sum Multi Criteria Optimization Approaches



Mortality based Relative Importance

Hospital Discharge based Relative Importance

### **Interactive Multi-Objective Decision Making**



### **Back to the Diabetes Case Study**

Define Disparity for each criteria *j* as:

$$f_j(\mathbf{x}) = \sum_{i=1}^n (z_{ij} - x_i)_+, \quad j = 1, \dots, m,$$
  
where  $(\cdot)_+ = \max\{\cdot, 0\}.$ 

$$\min_{\mathbf{x}\in\mathcal{S}}\max_{\mathbf{w}\in\mathcal{P}}\quad \sum_{j=1}^m w_j f_j(\mathbf{x}).$$

 $z_{ij}$  is budget share for state *i* if criteria *j* is the only criteria used for a proportional budget allocation according to this criteria.

 $x_i$  is the decision variable (model recommended budget)

$$S = \{ \mathbf{x} \mid \sum_{i=1}^{n} x_i = 1, x_i \ge 0, i = 1, \dots, n \}.$$
Mortality and Discharge Ctrs
$$\mathcal{P}$$
Perturbation to
each extreme
around a center
$$\mathcal{P}$$

### What did we learn?

	CDC Bu	$_{ m idget}$	Mortality	Mag	nitude of	Budget Change			
State	Dollar	Prop.	$\mathbf{Center}$	0.1	0.2	0.5	0.9	Relative	Absolute
AK	\$424,661	2.32%	0.24%	0.25%	0.32%	1.78%	1.78%	7.4	1.54%
AL	\$291,564	1.59%	3.25%	3.14%	3.14%	1.26%	1.11%	2.9	2.14%
AR	\$464,177	2.54%	1.80%	1.80%	1.79%	1.42%	1.34%	1.3	0.46%
AZ	\$250,017	1.37%	3.10%	3.10%	3.10%	1.61%	1.61%	1.9	1.49%
CA	\$1,043,922	5.71%	16.14%	16.14%	15.92%	13.71%	15.16%	1.2	2.43%
CO	\$507,359	2.77%	1.44%	1.44%	1.44%	1.44%	1.44%	1.0	0.00%
CT	\$252,782	1.38%	1.45%	1.47%	1.47%	1.47%	1.20%	1.2	0.28%
DC	\$261,917	1.43%	0.31%	0.31%	0.40%	4.68%	4.68%	15.3	4.37%
DE	\$386,912	2.12%	0.52%	0.54%	0.55%	3.41%	2.58%	6.6	2.89%
$\operatorname{FL}$	\$694,394	3.80%	10.40%	10.40%	10.20%	9.36%	10.20%	1.1	1.04%
GA	\$369,150	2.02%	6.44%	6.43%	6.43%	4.31%	3.92%	1.6	2.51%
HI	\$328,887	1.80%	0.56%	0.57%	0.69%	3.14%	3.14%	5.6	2.58%
IA	\$229,862	1.26%	1.31%	1.32%	1.37%	1.74%	1.74%	1.3	0.43%
ID	\$330,291	1.81%	0.79%	0.80%	0.85%	1.92%	1.92%	2.4	1.13%

 Weight center and regions matter – though solutions are "stable" when perturbations are "reasonable"
 Some states may be significantly underfunded

### **Lessons Learned: Discharge Versus Mortality Center**

	Mortality	Hospital Discharge	Budget	t Change				
State	Center	Center	0.1	0.2	0.5	0.9	Rel.	Abs.
AK	0.24%	0.38%	1.78%	1.78%	1.78%	1.78%	4.7	1.40%
AL	3.25%	2.52%	1.26%	1.14%	1.06%	1.11%	2.4	1.46%
$\mathbf{AR}$	1.80%	1.68%	1.51%	1.46%	1.36%	1.34%	1.3	0.34%
AZ	3.10%	2.08%	1.61%	1.61%	1.61%	1.48%	1.4	0.61%
CA	16.14%	17.54%	14.29%	14.55%	15.11%	15.16%	1.2	3.24%
CO	1.44%	1.45%	1.44%	1.44%	1.44%	1.44%	1.0	0.01%
CT	1.45%	1.53%	1.47%	1.47%	1.28%	1.20%	1.3	0.33%
DC	0.31%	0.52%	4.68%	4.68%	4.68%	4.68%	9.0	4.15%
DE	0.52%	0.59%	2.58%	3.83%	2.58%	2.58%	6.5	3.24%
$\mathbf{FL}$	10.40%	10.20%	9.76%	9.76%	9.98%	10.20%	1.0	0.44%
GA	6.44%	4.28%	3.92%	3.92%	3.92%	3.92%	1.1	0.36%
HI	0.56%	0.97%	3.14%	3.14%	3.14%	3.14%	3.2	2.16%
IA	1.31%	1.66%	1.66%	1.66%	1.66%	1.66%	1.0	0.00%
ID	0.79%	1.07%	1.92%	1.92%	1.92%	1.92%	1.8	0.84%

Initial recommendations are different but they approach each other as weight regions are enlarged

Rest of the conclusions are similar!

### **Policy Implications: Reverse Engineering**

Find Relative importance (weights) from a recommended budget.



 Recommended weights emphasize regular self foot exam (1-3) and eye exam (2-2), blood glucose self checkup (4-2) and patient education (7-1) to reduce geographical disparity.
 In short, proper physician follow-up and education (7-1, 7-2) will help reduce disparity.

### Conclusion

- Highly versatile technology for data analysis and decision making
- It is well developed with continued development
- Numerous use examples in areas other than health
- Whenever your problems can be framed with an "objective" to be minimized/maximized, you have an optimization problem!!!

# Thank you